MMV welcomes proposals in the following four areas:

1. **Compounds addressing the key priorities of the malaria eradication agenda**
   New families of molecules in the hit-to-lead and lead optimization phases are sought that:
   - kill or reactivate hypnozoites for use as part of a *P. vivax* radical cure;
   - have dual activity against asexual and sexual stages for treatment and transmission blocking;
   - are novel and without G6PD deficiency liabilities.

2. **Assays addressing liver stage vivax**
   - Novel, robust and validated *in vitro* or *in vivo* models of vivax liver stages are sought that are suitable for immediate compound testing.
   See MMV’s website for specific details.

3. **Asexual liver and blood stages**
   Novel chemical series that have one or more of the following key features:
   - A novel mechanism of action;
   - A long half-life (ideally >10h in rodents) and confirmed *in vivo* efficacy;
   - For advanced series, we are seeking compounds with, ideally, a predicted human half-life >100h and a predicted single human dose <1g.

Please read the target product profiles on MMV’s website for more information. Early target validation falls outside of our mandate.

4. **Resistant strains**
   To help select future antimalarial candidate drugs, we would like to hear from groups who have stable parasite cultures that show significant resistance to any of the drugs listed below:
   - Piperaquine, Pyronaridine, Mefloquine, Amodiaquine, Lumefantrine

   If resistance is confirmed then MMV would welcome the opportunity to add a resistant mutant to our screening panel.

Application templates are available at: [www.mmv.org](http://www.mmv.org)

Deadline for applications: 14 March 2014